EBAG9 and neoplasm: At more than 6 months, Eμ-Tcl1 Ebag9+/– mice had a further increased tumor load in spleen (for Eμ-Tcl1 Ebag9+/–, mean ± SEM, 49.4% ± 5.6%; for Eμ-Tcl1 Ebag9–/–, 30.3% ± 4.3%) and peripheral blood (for Eμ-Tcl1Ebag9+/–, mean ± SEM, 46.6% ± 5.6%; for Eμ-Tcl1Ebag9–/–, 25.9% ± 4.5%), whereas tumor load in Eμ-Tcl1 Ebag9–/– mice was substantially lower (Figure 1, D and E, and Supplemental Figure 1A).